

Researcher Profile Or Tena Cp And Cã

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2774903/publications.pdf>

Version: 2024-02-01

63
papers

3,897
citations

218677

26
h-index

123424

61
g-index

70
all docs

70
docs citations

70
times ranked

4567
citing authors

#	ARTICLE	IF	CITATIONS
1	Exercise-driven exacerbation of inflammation: contribution of animal models of rheumatoid arthritis and spondyloarthritis. <i>Connective Tissue Research</i> , 2022, 63, 425-442.	2.3	3
2	Factors associated to COVID-19 vaccine acceptance in Mexican patients with rheumatic diseases: A cross-sectional and multicenter study. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-10.	3.3	4
3	Recommendations of the Mexican College of Rheumatology for the management of spondyloarthritis. <i>ReumatologÃa ClÃnica (English Edition)</i> , 2021, 17, 37-45.	0.3	0
4	Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. <i>New England Journal of Medicine</i> , 2021, 384, 1227-1239.	27.0	143
5	Stability of housekeeping genes in inflamed joints of spontaneous and collagen-induced arthritis in DBA/1 mice. <i>Inflammation Research</i> , 2021, 70, 619-632.	4.0	4
6	Recommendations of the Mexican College of Rheumatology for the management of psoriatic arthritis. <i>ReumatologÃa ClÃnica (English Edition)</i> , 2021, 17, 611-621.	0.3	0
7	Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double-blind Withdrawal Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 1663-1672.	5.6	13
8	Prevalence of complementary and alternative medicine despite limited perceived efficacy in patients with rheumatic diseases in Mexico: Cross-sectional study. <i>PLoS ONE</i> , 2021, 16, e0257319.	2.5	7
9	Inflammatory Foot Involvement in Spondyloarthritis: From Tarsitis to Ankylosing Tarsitis. <i>Frontiers in Medicine</i> , 2021, 8, 730273.	2.6	3
10	Alteraciones temporomandibulares y odontolÃ³gicas en pacientes con artritis reumatoide. <i>ReumatologÃa ClÃnica</i> , 2020, 16, 262-271.	0.5	5
11	Consenso ASAS en nomenclatura en espaÃ±ol para las espondiloartritis. <i>ReumatologÃa ClÃnica</i> , 2020, 16, 333-338.	0.5	4
12	Oral health and orofacial function in patients with rheumatoid arthritis. <i>Rheumatology International</i> , 2020, 40, 445-453.	3.0	11
13	Temporomandibular and odontological abnormalities in patients with rheumatoid arthritis. <i>ReumatologÃa ClÃnica (English Edition)</i> , 2020, 16, 262-271.	0.3	3
14	Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. <i>Lancet, The</i> , 2020, 395, 53-64.	13.7	138
15	Trial of Anifrolumab in Active Systemic Lupus Erythematosus. <i>New England Journal of Medicine</i> , 2020, 382, 211-221.	27.0	725
16	Syndemic and syndemogenesis of low back pain in Latin-American population: a network and cluster analysis. <i>Clinical Rheumatology</i> , 2020, 39, 2715-2726.	2.2	13
17	Positive transcriptional response on inflammation and joint remodelling influenced by physical exercise in proteoglycan-induced arthritis: An animal study. <i>Bone and Joint Research</i> , 2020, 9, 36-48.	3.6	9
18	Ashwin Gene Expression Profiles in Oocytes, Preimplantation Embryos, and Fetal and Adult Bovine Tissues. <i>Animals</i> , 2020, 10, 276.	2.3	0

#	ARTICLE	IF	CITATIONS
19	We Got Your Back! Help Care Seeking and Caregiving in Mexican Indigenous Men With Ankylosing Spondylitis. <i>American Journal of Men's Health</i> , 2019, 13, 155798831987201.	1.6	0
20	Predictive factors related to the progression of periodontal disease in patients with early rheumatoid arthritis: a cohort study. <i>BMC Oral Health</i> , 2019, 19, 240.	2.3	14
21	Exercise Exacerbates the Transcriptional Profile of Hypoxia, Oxidative Stress and Inflammation in Rats with Adjuvant-Induced Arthritis. <i>Cells</i> , 2019, 8, 1493.	4.1	10
22	Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors. <i>Arthritis and Rheumatology</i> , 2019, 71, 599-611.	5.6	142
23	Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies. <i>Reumatología Clínica</i> , 2019, 15, 43-53.	0.5	1
24	Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial. <i>Journal of Rheumatology</i> , 2018, 45, 1085-1092.	2.0	28
25	Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 495-499.	0.9	10
26	Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2018, 45, 456-464.	2.0	13
27	Parálisis diafragmática en granulomatosis eosinofílica con poliangeítis. <i>Reumatología Clínica</i> , 2018, 14, 61-62.	0.5	1
28	Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. <i>Lancet, The</i> , 2018, 392, 2441-2451.	13.7	251
29	Epidemiology and socioeconomic impact of the rheumatic diseases on indigenous people: an invisible syndemic public health problem. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1397-1404.	0.9	31
30	DNA Damage and Deficiencies in the Mechanisms of Its Repair: Implications in the Pathogenesis of Systemic Lupus Erythematosus. <i>Journal of Immunology Research</i> , 2018, 2018, 1-18.	2.2	21
31	Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. <i>Lancet, The</i> , 2017, 390, 457-468.	13.7	360
32	Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors. <i>RMD Open</i> , 2017, 3, e000416.	3.8	33
33	Latitude gradient influences the age of onset of rheumatoid arthritis: a worldwide survey. <i>Clinical Rheumatology</i> , 2017, 36, 485-497.	2.2	25
34	Oxidative Stress Relevance in the Pathogenesis of the Rheumatoid Arthritis: A Systematic Review. <i>BioMed Research International</i> , 2016, 2016, 1-14.	1.9	203
35	Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1975.	7.4	95
36	VX509 (Decernotinib), an Oral Selective JAK3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 46-55.	5.6	110

#	ARTICLE	IF	CITATIONS
37	Hypoxia and its implications in rheumatoid arthritis. <i>Journal of Biomedical Science</i> , 2016, 23, 62.	7.0	110
38	Prevalence of rheumatic diseases in Raramuri people in Chihuahua, Mexico: a community-based study. <i>Clinical Rheumatology</i> , 2016, 35, 43-52.	2.2	18
39	Molecular mechanisms of bone formation in spondyloarthritis. <i>Joint Bone Spine</i> , 2016, 83, 394-400.	1.6	26
40	Bone Proliferation in Ankylosing Tarsitis Might Involve Mechanical Stress, and Hormonal and Growth Factors. <i>Journal of Rheumatology</i> , 2015, 42, 2210-2210.	2.0	5
41	The Danger Model Approach to the Pathogenesis of the Rheumatic Diseases. <i>Journal of Immunology Research</i> , 2015, 2015, 1-23.	2.2	14
42	Further international adaptation and validation of the Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire. <i>Rheumatology International</i> , 2015, 35, 669-675.	3.0	8
43	Bone Lineage Proteins in the Enteses of the Midfoot in Patients with Spondyloarthritis. <i>Journal of Rheumatology</i> , 2015, 42, 630-637.	2.0	17
44	Subcutaneous Abatacept for the Treatment of Rheumatoid Arthritis: Longterm Data from the ACQUIRE Trial. <i>Journal of Rheumatology</i> , 2014, 41, 629-639.	2.0	33
45	Treatment of Multicentric Reticulohistiocytosis With Tocilizumab. <i>Journal of Clinical Rheumatology</i> , 2013, 19, 272-276.	0.9	26
46	Assessment of different decalcifying protocols on Osteopontin and Osteocalcin immunostaining in whole bone specimens of arthritis rat model by confocal immunofluorescence. <i>International Journal of Clinical and Experimental Pathology</i> , 2013, 6, 1972-83.	0.5	19
47	Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1629-1635.	0.9	296
48	Tumor Necrosis Factor- $\hat{\pm}$ Promoter Polymorphisms in Mexican Patients With Spondyloarthritis. <i>Human Immunology</i> , 2006, 67, 826-832.	2.4	36
49	Low grade radiographic sacroiliitis as prognostic factor in patients with undifferentiated spondyloarthritis fulfilling diagnostic criteria for ankylosing spondylitis throughout follow up. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 642-646.	0.9	65
50	Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 84-87.	0.9	61
51	Relationship between disease activity and infection in patients with spondyloarthropathies. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 1338-1340.	0.9	27
52	Association study of LMP gene polymorphisms in Mexican patients with spondyloarthritis. <i>Human Immunology</i> , 2004, 65, 1437-1442.	2.4	29
53	Microbe hunting in the joints. <i>Arthritis and Rheumatism</i> , 2003, 49, 479-482.	6.7	19
54	Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity. <i>Journal of Rheumatology</i> , 2003, 30, 2112-22.	2.0	86

#	ARTICLE	IF	CITATIONS
55	Development of a radiographic index to assess the tarsal involvement in patients with spondyloarthropathies. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 330-334.	0.9	17
56	Heat shock protein 70 gene polymorphisms in Mexican patients with spondyloarthropathies. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 48-51.	0.9	81
57	Effect of HLA-B and HLA-DR genes on susceptibility to and severity of spondyloarthropathies in Mexican patients. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 714-717.	0.9	45
58	A 26 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 941-942.	0.9	104
59	Innate immunity in host-microbial interactions: Beyond B27 in the spondyloarthropathies. <i>Current Opinion in Rheumatology</i> , 2002, 14, 373-382.	4.3	20
60	The juvenile-onset spondyloarthritides: rationale for clinical evaluation. <i>Best Practice and Research in Clinical Rheumatology</i> , 2002, 16, 551-572.	3.3	21
61	Relation between adverse events associated with allopurinol and renal function in patients with gout. <i>Annals of the Rheumatic Diseases</i> , 2001, 60, 981-983.	0.9	144
62	Comparison of two schedules for administering oral low-dose methotrexate (weekly versus) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 467 T randomized study. <i>Arthritis and Rheumatism</i> , 1999, 42, 2160-2165.	6.7	20
63	JUVENILE-ONSET SPONDYLOARTHROPATHIES. <i>Rheumatic Disease Clinics of North America</i> , 1997, 23, 569-598.	1.9	78